Accessibility Tools

Skip to main content

You must be a logged-in member of UHMS or a subscriber to the UHMS Journal in order to download the articles listed within these pages. If you are a member or subscriber, please log in using the Log In button above. If you would like to purchase a membership or a subscription, use the buttons below.

Search UHM/UBR

Nitrofurantoin-Induced Hemolytic Anemia and Methemoglobinemia in G6PD Deficiency Treated With Hyperbaric Oxygen Treatment

Nitrofurantoin-Induced Hemolytic Anemia and Methemoglobinemia in G6PD Deficiency Treated With Hyperbaric Oxygen Treatment

Description

Padhiyar V, Maitra A, Singh C, Tulara N. Nitrofurantoin-Induced Hemolytic Anemia and

Methemoglobinemia in G6PD Deficiency Treated With Hyperbaric Oxygen Treatment. Undersea

Hyperb Med. 2026 Second Quarter; 53(2):235-242.

Introduction: Methemoglobinemia is a rare but potentially serious condition characterized by an

increased level of methemoglobin in the blood, which impairs oxygen delivery to tissues. It occurs

when hemoglobin’s ferrous iron (Fe2+) is oxidized to ferric iron (Fe3+), rendering it unable to bind oxygen

effectively. This leads to tissue hypoxia, which can manifest clinically as cyanosis, shortness of breath,

fatigue, and, in severe cases, organ dysfunction.

Case Report: Nitrofurantoin-induced hemolytic anemia and methemoglobinemia in patients with

glucose-6-phosphate dehydrogenase (G6PD) deficiency are rare but potentially life-threatening

complications. We present the case of a 64-year-old female with G6PD deficiency who developed acute

hemolytic anemia and methemoglobinemia following nitrofurantoin therapy for a urinary tract infection.

Her initial symptoms included fatigue, jaundice, and dyspnea, progressing rapidly to severe anemia and

cyanosis. Laboratory investigations confirmed hemolysis and elevated methemoglobin levels.

Although methemoglobinemia is commonly treated with methylene blue, its use in G6PD-deficient

patients can exacerbate hemolysis. In this case, we promptly discontinued nitrofurantoin and managed

the patient with hyperbaric oxygen treatment, intravenous ascorbic acid, and other supportive measures.

Despite aggressive treatment, she required blood transfusion support and prolonged hospitalization.

Discussion: This case underscores the importance of recognizing the potential for nitrofurantoin-induced

hemolytic anemia and methemoglobinemia in G6PD-deficient individuals, highlighting the need for

careful drug selection and vigilant monitoring in this population.

Keywords: case report; glucose-6-phosphate dehydrogenase deficiency; hemolytic anemia; hyperbaric

oxygen treatment; methemoglobinemia; nitrofurantoin

×